 |
|
Variation in prostate stem cell antigen gene raises bladder cancer risk
August 03, 2009HOUSTON - Researchers have pinpointed a specific gene variation that causes increased risk of urinary bladder cancer, according to a scientific team led by The University of Texas M. D. Anderson Cancer Center.
These findings were reported today in the advance online publication of Nature Genetics, and determined that people with the variant had a 30 percent to 40 percent higher risk for bladder cancer. Scientists hope the results of this large, multi-site international study may help determine who is at high risk to contract this deadly cancer, which may lead to better survival rates and the development of chemopreventive interventions.
"With this research, we were able to find a novel specific gene and a functional variation that are independent of the previous suspects. We found a 'why' to many of the questions about genetic causes of bladder cancer," said Xifeng Wu, M.D., Ph.D., professor in M. D. Anderson's Department of Epidemiology, Division of Cancer Prevention and Population Sciences, the lead and corresponding author of this publication. "The neighboring genomic region has been identified previously as a possible problem for breast, prostate, colorectal and bladder cancer, but we didn't know why."
Genetic risk factors have been elusive
Bladder cancer is the fourth most common cancer in men in the United States. In this country, it is projected that more than 68,800 new cases will be diagnosed and approximately 14,400 people will die because of the disease this year.
Cigarette smoking and occupational exposure to certain chemicals are known risk factors, but almost one-third of people who get the disease have an inherited genetic susceptibility. People with first-degree relatives with bladder cancer have a 50 percent to 100 percent higher risk of getting the disease.
However, the exact genetic explanation for bladder cancer has remained elusive, and this study may have helped to solve some of the puzzles, Wu said.
Prostate stem cell antigen (PSCA) is over-expressed in prostate cancer, and the level of PSCA increases with tumor grade and stage. However, the cellular function of PSCA in prostate cancer is not clear.
While PSCA's involvement in bladder cancer had been suggested previously, this is the first time it has been linked definitively.
6,667 cases, 39,590 controls
The first step of this study was a genomewide evaluation of 969 people with bladder cancer and 954 healthy people. To validate their findings, researchers evaluated patients from three additional U.S. and nine European groups, for a total of 6,667 people with bladder cancer and 39,590 healthy people.
A variant in the PSCA gene (rs2294008) was associated consistently with bladder cancer. Researchers then re-examined the PSCA gene region and found rs2294008 was the only common missense genetic variation in the PSCA region. A missense mutation occurs at a single point in the genome and swaps one amino acid for another in a protein.
Low levels of PSCA were found in the bladders of healthy people, but it was over-produced in the majority of patients with bladder cancer. Previous reports suggest that measurement of PSCA in urine may be a simple and accurate marker to help diagnose bladder cancer.
Potential for chemoprevention, treatment
Next, the group plans to fully analyze data jointly with other participating centers, possibly uncovering additional genes for bladder cancer.
Wu said she hopes the group's findings will help targeted bladder cancer prevention efforts.
"When we've identified all the genes that are linked to bladder cancer, we plan to develop a web-based tool so physicians can calculate accurately and easily a patient's risk of getting the disease," she said. "Early identification of risk may help save lives with chemoprevention or early treatment."
In addition, Wu's team is working with a hospital in Spain to compare findings of the study to clinical outcomes. "How do these genes affect survival, recurrence and progression of bladder cancer?" she said. "As we get more information, we hope to be able to predict clinical outcomes and optimize therapy."
University of Texas M. D. Anderson Cancer Center
Genetic risk factors have been elusive
Bladder cancer is the fourth most common cancer in men in the United States. In this country, it is projected that more than 68,800 new cases will be diagnosed and approximately 14,400 people will die because of the disease this year.
Cigarette smoking and occupational exposure to certain chemicals are known risk factors, but almost one-third of people who get the disease have an inherited genetic susceptibility. People with first-degree relatives with bladder cancer have a 50 percent to 100 percent higher risk of getting the disease.
However, the exact genetic explanation for bladder cancer has remained elusive, and this study may have helped to solve some of the puzzles, Wu said.
Prostate stem cell antigen (PSCA) is over-expressed in prostate cancer, and the level of PSCA increases with tumor grade and stage. However, the cellular function of PSCA in prostate cancer is not clear.
While PSCA's involvement in bladder cancer had been suggested previously, this is the first time it has been linked definitively.
6,667 cases, 39,590 controls
The first step of this study was a genomewide evaluation of 969 people with bladder cancer and 954 healthy people. To validate their findings, researchers evaluated patients from three additional U.S. and nine European groups, for a total of 6,667 people with bladder cancer and 39,590 healthy people.
A variant in the PSCA gene (rs2294008) was associated consistently with bladder cancer. Researchers then re-examined the PSCA gene region and found rs2294008 was the only common missense genetic variation in the PSCA region. A missense mutation occurs at a single point in the genome and swaps one amino acid for another in a protein.
Low levels of PSCA were found in the bladders of healthy people, but it was over-produced in the majority of patients with bladder cancer. Previous reports suggest that measurement of PSCA in urine may be a simple and accurate marker to help diagnose bladder cancer.
Potential for chemoprevention, treatment
Next, the group plans to fully analyze data jointly with other participating centers, possibly uncovering additional genes for bladder cancer.
Wu said she hopes the group's findings will help targeted bladder cancer prevention efforts.
"When we've identified all the genes that are linked to bladder cancer, we plan to develop a web-based tool so physicians can calculate accurately and easily a patient's risk of getting the disease," she said. "Early identification of risk may help save lives with chemoprevention or early treatment."
In addition, Wu's team is working with a hospital in Spain to compare findings of the study to clinical outcomes. "How do these genes affect survival, recurrence and progression of bladder cancer?" she said. "As we get more information, we hope to be able to predict clinical outcomes and optimize therapy."
University of Texas M. D. Anderson Cancer Center
Bladder Cancer Current Events and Bladder Cancer News RSSMedicare reimbursement change meant to save money has opposite effect
Increased Medicare payments to physicians for outpatient surgeries for bladder cancer have led to a dramatic rise in the number of these procedures being performed and an overall increase in cost to the healthcare system.
Prediction model superior to traditional criteria in bladder treatment decision
A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy.
Hopkins scientists find cells responsible for bladder cancer's spread
Johns Hopkins scientists have tracked down a powerful set of cells in bladder tumors that seem to be primarily responsible for the cancer's growth and spread using a technique that takes advantage of similarities between tumor and organ growth.
UT Southwestern researchers investigate high-risk populations for bladder-cancer screenings
A new study by UT Southwestern Medical Center researchers sheds light on the challenges involved in identifying which high-risk population would benefit most from bladder-cancer screening.
DKK-3 and WIF-1: Proteins related to liver cancer development?
Liver cancer is one of the most fatal human malignancies and the third most frequent cause of tumor-related death, about half a million people globally each year.
Certain ecologic factors associated with greater risk of bladder cancer
Persons drinking well water (as opposed to public supply) may be at an increased risk of bladder cancer, according to new research from the University of Alabama at Birmingham. Researchers will present data about the relationship between bladder cancer and certain ecologic factors including water source and UV radiation levels at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence
Making tumors inside the bladder fluoresce red under blue light allows physicians to more easily find and remove them, substantially reducing the rate at which these cancers come back, says a Mayo Clinic physician who is presenting results of a large, multicenter international clinical trial.
Genetic Variants Predict Recurrence of Bladder Cancer, Patient Survival
Scientists at The University of Texas M. D. Anderson Cancer Center have discovered genetic variations in the inflammation pathway that reduce the likelihood of recurrence and increase survival of patients with non-muscle invasive bladder cancer (NMIBC) who are treated with mainstream therapy.
More intense bladder cancer treatment does not improve survival, U-M study finds
Despite enduring more invasive tests and medical procedures, patients who were treated aggressively for early stage bladder cancer had no better survival than patients who were treated less aggressively.
New Discovery Raises Doubts About Use of Certain Targeted Therapies in Bladder Cancer
Researchers at the University of Virginia Health System have found that one of the genes commonly thought to promote the growth and spread of some types of cancers is in fact beneficial in bladder cancer - a major discovery that could significantly alter the way bladder cancers are treated in the future.
More Bladder Cancer Current Events and Bladder Cancer News Articles
 |
Bladder Cancer: A Resource Guide for Patients and Their Families by Gary Dunetz (Author) If you, a loved one or friend has been diagnosed with bladder cancer, learning the basics is of utmost importance. It is essential to understand the nature of the disease, the work up and variety of treatments which are available. This book is comprehensive yet user friendly. It is written in a question and answer format in conversational tone. The physician author is a clinical urologist who has guided many individuals with bladder cancer through diagnosis and the various forms of treatment. This resource should enable those with bladder cancer and their family and friends to face this challenge with reason. After reading this book, you will be able to make an informed decision as you collaborate with your physician to regain your health. This book is written to allow the reader to have... |
 |
100 Questions & Answers About Bladder Cancer by Pamela Ellsworth (Author), Brett Carswell (Author) Approximately 62,000 people are diagnosed with bladder cancer each year, making bladder cancer the fourth most common type of cancer in men and the eighth most common type in women. Whether you're a newly diagnosed bladder cancer patient, a survivor, or a friend or relative of either, this book offers help. The only book to provide both the doctor's and patient's views, 100 Questions & Answers About Bladder Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, coping strategies, sources of support, and much more. Written by two prominent urologists, with "insider" advice from actual patients, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease. |
 |
Johns Hopkins Patients' Guide to Bladder Cancer (Johns Hopkins Patients Guides) by Mark L. Gonzalgo (Editor) (Author) Johns Hopkins Patients' Guide to Bladder Cancer is a concise, easy-to-follow how to guide that puts you on a path to wellness by explaining bladder cancer treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment. |
 |
Bladder Cancer (Cleveland Clinic Guide) by M D Raghavan (Author), Kathleen Tuthill (Author) Cancer that arises in the bladder is one of the most common malignancies in industrialized societies and yet is not well understood in the community at large. Bladder Cancer: A Cleveland Clinic Guide provides simple, non-medical explanations of this disease for people who have to deal with this illness, either as patients or as those who care for these patients. |
 |
The Cleveland Clinic Guide to Bladder Cancer (Cleveland Clinic Guides) by Derek Raghavan (Author) Expert medical advice from the Chairman of the Cleveland Clinic Taussig Cancer Institute. Every year, 60,000 people are diagnosed with bladder cancer. If found early, bladder cancer is highly treatable,but it does have a high rate of recurrence. Staying informed is key for those facing a diagnosis as well as for those living with the disease. Dr. Derek Raghavan is one of the country’s leading experts in this field and, as the Chairman of the Cleveland Clinic Taussig Cancer Institute, he has access to the latest research and studies. In The Cleveland Clinic Guide to Bladder Cancer, he provides all of the essential information needed to understand and manage the challenges of bladder cancer. |
 |
The Guide to Living with Bladder Cancer by Dr. Mark P. Schoenberg MD FACS (Author) Johns Hopkins Univ., Baltimore, MD. Text for families and patients facing this disease. Discusses the structure and function of the urinary tract, an overview of bladder cancer and risk factors, symptoms, surgery, life after surgery, principles of chemotherapy, tests and diagnosis, and major surgical procedures. Hardcover, soft not available |
 |
Treatment and Management of Bladder Cancer (with CD) by Seth P. Lerner (Editor), Mark Schoenberg (Editor), Cora Sternberg (Editor) Bladder cancer is an international public health problem affecting millions of people in both developed and underdeveloped nations. This major urologic malignancy was one of the first cancers to be linked to occupational and environmental exposure to carcinogens. Bladder cancer is the 5th most common cancer of American men and the 8th most common cancer of American women. Sixty thousand new cases of the disease are diagnosed each year in the US alone; disease prevalence is high in western nations due to the predominance of the chronic relapsing form of cancer that occurs in these countries (USA prevalence estimated to be 600,000; NCI-SEER database). This single fact makes bladder cancer one of the most expensive cancers to treat. Treatment and Management of Bladder Cancer, drawing on... |
 |
Bladder Cancer Awareness Ribbon Mouse Pad by MyHeritageWear.com The Bladder Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Bladder Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Bladder Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Fight Against Bladder Cancer T-shirt Large White by Shop Zeus |
 |
Bladder Cancer (Fast Facts) by Michael Bailey (Author), Michael Sarosdy (Author) Bladder cancer is a common tumor and primary care physicians can expect to see at least three new cases per year. This new edition of FAST FACTS: BLADDER CANCER features: New chapters on palliation and oncology. New expanded coverage of chemotherapy and radiography. Includes the very latest evidence-based guidelines on diagnosis and therapeutics. Future Trends chapter reviews advances in early diagnosis and therapeutics. |
| © 2010 BrightSurf.com |